Clinical Trials Logo

Pulmonary Hypertension clinical trials

View clinical trials related to Pulmonary Hypertension.

Filter by:

NCT ID: NCT05983250 Recruiting - Clinical trials for Pulmonary Hypertension

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

LEVEL
Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of TNX-103 (levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).

NCT ID: NCT05958901 Recruiting - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension Observational Study

Start date: July 12, 2023
Phase:
Study type: Observational

The purpose of this study is to establish the large PH cohort and biological database in China, aiming for precision medicine to optimize diagnosis and treatment choices.

NCT ID: NCT05935865 Recruiting - Clinical trials for Pulmonary Hypertension

Monitoring of the Influence of Approved PH-therapies RV-PA Coupling

Start date: February 13, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the acute (days) changes in right ventricular functions caused by initiation of pharmacological therapies in patients with precapillary pulmonary hypertension. The main question it aims to answer is: • Course of afterload and intrinsic contractility throughout the hospital stay Participants will be equipped with a device for continuous monitoring and recording of the right ventricular pressure signal.

NCT ID: NCT05935605 Recruiting - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension in Left Heart Disease

Start date: July 20, 2023
Phase:
Study type: Observational

The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.

NCT ID: NCT05903001 Recruiting - Asthma Clinical Trials

Diaphragmatic Function as a Biomarker

DFUNBIO
Start date: July 1, 2023
Phase:
Study type: Observational

Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.

NCT ID: NCT05901168 Recruiting - Clinical trials for Pulmonary Hypertension

Acute Responses of Active Video Games and Traditional Exercise Program in in Patients With Pulmonary Hypertension

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

At least 20 volunteers with a diagnosis of Pulmonary Hypertension in the Department of Cardiology of Dokuz Eylul University and who meet the criteria for follow-up and inclusion will participate in the study. The aim of this study is to examine the acute effects of active video games compared to traditional exercise and the effects on energy expenditure and enjoyment in PD patients. Demographic and clinical information of the participants will be questioned. Active video games and home-based exercise sessions will be held randomly/by the same person with a break of at least 1 day in 1 week, lasting 20 minutes. Heart rate, blood pressure, shortness of breath and oxygen saturation will be measured before and after the sessions. In addition, energy expenditure, heart rate, perceived exertion, shortness of breath and oxygen saturation will be recorded during the sessions. In addition, arterial stiffness will be evaluated with a non-invasive device. At the end of the sessions, whether people like active video games or not will be questioned with a 10-point Likert-type scale.

NCT ID: NCT05896579 Recruiting - COPD Clinical Trials

Identifying Right Ventricular Dysfunction in COPD Through Right Heart Catheterization, Imaging and Exercise

Start date: August 22, 2023
Phase: N/A
Study type: Interventional

This study plans to learn more about heart function among individuals with chronic obstructive pulmonary disease (COPD). In particular, the investigators want to understand the different patterns of right ventricular response to pulmonary hypertension (high pressure in the lungs) during rest and exercise. By identifying patterns of right ventricular dysfunction, this study will help identify better treatments for patients with COPD in the future.

NCT ID: NCT05873387 Recruiting - Clinical trials for Pulmonary Hypertension

Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope

Start date: July 12, 2023
Phase:
Study type: Observational

The major goal of the study is to determine whether phonocardiography (using the Eko DUO stethoscope which can capture a three lead ECG reading) can present features that relate to the presence of PH diagnosed by echocardiography or right heart catheterization (RHC), and therefore have a potential to assist the provider to suspect PH.

NCT ID: NCT05856461 Recruiting - Atrial Fibrillation Clinical Trials

Pulmonary Artery Denervation in Patients With Atrial Fibrillation and Group 2 of Pulmonary Hypertension

PADN+AF
Start date: May 22, 2023
Phase: N/A
Study type: Interventional

The goal of the study is to compare efficacy and safety of the pulmonary artery denervation procedure combined with atrial fibrillation ablation versus atrial fibrillation ablation alone in patients with paroxysmal and persistent atrial fibrillation and group 2 of the pulmonary hypertension

NCT ID: NCT05844462 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

ERASE PH-COPD
Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.